Anzeige
Mehr »
Login
Dienstag, 26.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
500% Potenzial: Warum Analysten von diesem Uran-Explorer begeistert sind!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
1.339 Leser
Artikel bewerten:
(2)

Avantor Launches New Protein A Chromatography Resin - PROchievA - that Provides Supply Chain Flexibility and Improves Downstream Purification Performance for Monoclonal Antibodies (mAbs) Production

Finanznachrichten News

New high purity resin advances bioprocessing and brings choice and efficiencies to mAbs production workflow processes and protocols

Monoclonal antibody drugs treat a wide variety of clinical indications - for cancer treatments, mAbs enlist natural immune system functions to fight the disease

RADNOR, Pennsylvania, March 18, 2020 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced a new recombinant Protein A affinity chromatography resin used to purify antibodies during mAbs production.

Avantor provides choice with new Protein A chromatography resin - PROchievA

Healthcare demand is increasing rapidly across most of the world, driven principally by aging populations, an increased prevalence of chronic diseases and improved access to healthcare. Monoclonal antibodies (mAbs) are proteins engineered to mimic or enhance the body's immune system. Biopharmaceutical manufacturers are pursuing ways to optimize the mAbs production process for increased efficiency, speed-to-market and cost reduction.

Protein A chromatography is a proven downstream purification step in manufacturing mAbs. Yet, there remains a need to reduce the total purification costs while improving purity and yield. The new Avantor recombinant protein A resin addresses these challenges.

Dr. Ger Brophy, Executive Vice President for Biopharma Production at Avantor, said, "Biopharmaceutical developers and manufacturers are urgently seeking new tools to drive more efficiency in their production processes. But they cannot compromise on quality standards as they work to provide powerful medicines to patients in a timely, safe and efficient manner."

In performance tests conducted against other best-in-class Protein A resins on the market today, Avantor's novel J.T.Baker BAKERBOND PROchievA recombinant protein A resin demonstrated high performance and provided best-in-class purification in the critical Protein A affinity chromatography step of mAbs manufacturing. Avantor's resin is compatible with current manufacturing standards which ensures continuity in workflow processes and compliance protocols.

"Our resin provides customers with a best-in-class, high-performing alternative to existing purification technology, with the benefit of greater supply chain flexibility and security," added Dr. Brophy.

The BAKERBOND PROchievA resin is manufactured at Avantor's Bridgewater Innovation Center in N.J., USA and is the company's latest example of driving improved bioprocessing efficiencies for the Life Sciences industry. Avantor recently teamed up with the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland to address downstream bottlenecks in buffer preparation when producing mAbs. More recently Avantor opened its ninth Innovation and Customer Support Center, which is located in Shanghai, China.

The new resin enhances Avantor's J.T.Baker family of products for biopharmaceutical research and production. Avantor's J.T.Baker brand chromatography products allow biopharma manufacturers to realize higher production efficiencies, meet stringent regulatory requirements and accelerate regulatory approval in bringing new therapies to market.

For more information about the BAKERBOND PROchievA resin and other J.T.Baker chromatography products, visit www2.avantorsciences.com/ProteinA.

For information about Avantor's biopharma capabilities in monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies and small molecule products, visit www.avantorsciences.com/en/biopharma.html.

About Avantor
Avantor is a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries. The company operates in more than 30 countries and delivers an extensive portfolio of products and services. As our channel brand, VWR offers an integrated, seamless purchasing experience that is optimized for the way our customers do business. We set science in motion to create a better world. For information, visit www.avantorsciences.com.

Global Media Contact
Robert Donohoe
Senior Director, Corporate Communications
Avantor
Office: 610-386-6420
Mobile: 484-688-4730
Robert.Donohoe@avantorsciences.com

Avantor introduces new brand identity

Photo - https://mma.prnewswire.com/media/1122321/Avantor_Protein_A_PROchievA.jpg
Logo - https://mma.prnewswire.com/media/718849/avantor_Logo.jpg

© 2020 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.